DIMYRISTOYLPHOSPHATIDYLGLYCEROL, DL-

Details

Stereochemistry	MIXED
Molecular Formula	C34H67O10P
Molecular Weight	666.8635
Optical Activity	UNSPECIFIED
Defined Stereocenters	0 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure of DIMYRISTOYLPHOSPHATIDYLGLYCEROL, DL-

Structure Search

SMILES

CCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCCCCCCCC

InChI

InChIKey=BPHQZTVXXXJVHI-UHFFFAOYSA-N

InChI=1S/C34H67O10P/c1-3-5-7-9-11-13-15-17-19-21-23-25-33(37)41-29-32(30-43-45(39,40)42-28-31(36)27-35)44-34(38)26-24-22-20-18-16-14-12-10-8-6-4-2/h31-32,35-36H,3-30H2,1-2H3,(H,39,40)

HIDE SMILES / InChI

Description
Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=5587db37-f21a-4a39-a319-e1077032ced9&type=display | https://leadiant.com/wp-content/uploads/2018/12/Abelcet-PI-11302018.pdf

DIMYRISTOYLPHOSPHATIDYLGLYCEROL, DL- is a component of ABELCET® (Amphotericin B Lipid Complex Injection). It consists of amphotericin B complexed with two phospholipids in a 1:1 drug-to-lipid molar ratio. The two phospholipids, l-α-dimyristoylphosphatidylcholine and l-α-dimyristoylphosphatidylglycerol, are present in a 7:3 molar ratio. ABELCET® is indicated for the treatment of invasive fungal infections in patients who are refractory to or intolerant of conventional amphotericin B therapy. This is based on the open-label treatment of patients judged by their physicians to be intolerant to or failing conventional amphotericin B therapy.

Approval Year

Conditions

Condition	Modality	Targets	Highest Phase	Product
Funcgal Infection 1 Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5587db37-f21a-4a39-a319-e1077032ced9	Primary		Approved 8429	ABELCET Approved Use ABELCET® is indicated for the treatment of invasive fungal infections in patients who are refractory to or intolerant of conventional amphotericin B therapy. Launch Date 2010

Sample Use Guides

In Vivo Use Guide

The recommended daily dosage for adults and children is 5 mg/kg given as a single infusion. ABELCET® should be administered by intravenous infusion at a rate of 2.5 mg/kg/h. If the infusion time exceeds 2 hours, mix the contents by shaking the infusion bag every 2 hours.

Route of Administration: Intravenous

Name

Type

Language

DIMYRISTOYLPHOSPHATIDYLGLYCEROL, DL-

Common Name

English

ALFQ component DMPG

Common Name

English

1,2-DIMYRISTOYL-GLYCERO-3-PHOSPHO-(1'-RAC-GLYCEROL)

Common Name

English

14:0 PG

Common Name

English

Army Liposome Formulation component DMPG

Common Name

English

ALF component DMPG

Common Name

English

DMPG, DL-

Common Name

English

DMPG

Common Name

English

1,2-DIMYRISTOYL-GLYCERO-3-(PHOSPHO-RAC-(1-GLYCEROL))

Common Name

English

DMPG, (±)-

Common Name

English

DIMYRISTOYLPHOSPHATIDYLGLYCEROL

Common Name

English

TETRADECANOIC ACID, 1,1'-(1-((((2,3-DIHYDROXYPROPOXY)HYDROXYPHOSPHINYL)OXY)METHYL)-1,2-ETHANEDIYL) ESTER

Common Name

English

Code System Code Type Description

CHEBI

60723